Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein. Ledipasvir (formerly GS-5885) is an experimental drug for the treatment of hepatitis C being developed by Gilead Sciences. It is currently in Phase III clinical trials.
A wide range of well-characterized bioactive molecules that covers various targets related to microbiology & virology, including CCR5, HSV and CMV etc. Facilitate your research towards the insights of infection, immune diseases and cancer etc.